Is Voyager Therapeutics, Inc. (VYGR) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 20.2% / 30% | 123.0% / 30% | 2.1% / 30% | 0.78% / 5% | ✗ NOT HALAL |
| DJIM | 20.2% / 33% | 123.0% / 33% | 2.1% / 33% | 0.78% / 5% | ✗ NOT HALAL |
| MSCI | 11.1% / 33% | 67.8% / 33% | 1.1% / 33% | 0.78% / 5% | ✗ NOT HALAL |
| S&P | 20.2% / 33% | 123.0% / 33% | 2.1% / 33% | 0.78% / 5% | ✗ NOT HALAL |
| FTSE | 11.1% / 33% | 67.8% / 33% | 1.1% / 50% | 0.78% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -227.6% | |
| Operating Margin | -172.4% | |
| Net Margin | -296.5% | |
| Return on Equity (ROE) | -48.3% | |
| Return on Assets (ROA) | -24.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$132M |
| Free Cash Flow | -$135M |
| Total Debt | $36M |
| Debt-to-Equity | 18.6 |
| Current Ratio | 7.6 |
| Total Assets | $252M |
Price & Trading
| Last Close | $4.13 |
| 50-Day MA | $3.92 |
| 200-Day MA | $3.94 |
| Avg Volume | 707K |
| Beta | 1.4 |
|
52-Week Range
$2.65
| |
About Voyager Therapeutics, Inc. (VYGR)
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Voyager Therapeutics, Inc. (VYGR) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Voyager Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Voyager Therapeutics, Inc.'s debt ratio?
Voyager Therapeutics, Inc.'s debt ratio is 20.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 11.1%.
What are Voyager Therapeutics, Inc.'s key financial metrics?
Voyager Therapeutics, Inc. has a market capitalization of $236M, and revenue of $40M. The company maintains a gross margin of -227.6% and a net margin of -296.5%. Return on equity stands at -48.3%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.